Program Overview
This CME program will highlight recent advances in S1P-based therapeutics for the treatment of patients with multiple sclerosis. The expert faculty, Dr. Clyde Markowitz, will first review the pharmacologic characteristics of all S1P-based therapies to aid in clinical decision making for the early intervention of patients diagnosed with multiple sclerosis (MS). Following, he will discuss long term efficacy and safety data for S1P therapeutics, including impact on physical and cognitive preservation. To conclude, Dr. Markowitz will analyze strategies to update current treatment plans and applied shared decision making to effectively integrate S1P-based therapies into the management and treatment of patients with MS.
Target Audience
MS specialists, other neurologists, and other healthcare professionals involved in the management of patients with multiple sclerosis
Learning Objective
- Review the various pharmacologic characteristics of all S1P-based therapies to aid in clinical decision making for the early intervention of patients diagnosed with MS.
- Analyze longer term efficacy and safety data for S1P therapeutics including impact on physical and cognitive preservation.
- Evaluate strategies to update current treatment plans and applied shared decision making to effectively integrate S1P-based therapies in the management of patients with MS.
Faculty
Clyde Markowitz
Associate Professor of Neurology
Director Emeritus, Multiple Sclerosis Center
Department of Neurology
Perelman School of Medicine
University of Pennsylvania
Philadelphia, PA
Disclosures of Relevant Financial Relationships
It is the policy of AcademicCME that all faculty, instructors, and planners disclose relevant financial relationships relating to the topics of this educational activity. Any relevant financial relationships are mitigated via a content review by planning committee members and faculty with no relevant financial relationships.
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CE activity:
| Faculty | Relationship Identified With: |
| Clyde Markowitz, MD | Consultant/Advisor: Alexion Pharmaceuticals, Inc.; ANI; Banner Life Sciences; Biogen; Bristol Myers Squibb; Cycle Pharmaceuticals Limited; EMD Serono; F. Hoffmann-La Roche Ltd; Genentech, Inc.; Sanofi; Horizon Therapeutics plc; Janssen Pharmaceuticals, Inc.; Novartis AG; Teva Pharmaceutical Industries Ltd; TG Therapeutics, Inc. |
Planners and Peer Reviewers
Timothy Hayes, MD, PhD; Kim Cheramie, MSN, RN-BC; Chelsey Simonds and Nicole McMenamin hereby state that they or their spouse/life partner do not have any relevant financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.
Accreditation Statement
In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Credit Designation Statements
AcademicCME designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditsTM.
Learners should only claim credit commensurate with the extent of their participation.
Financial Support
This activity has been supported by an independent educational grant from Bristol Myers Squibb.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Bristol Myers Squibb do not recommend the use of any agent outside of the labeled indications.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Method of Participation
In order to claim credit, participants must complete the following:
- Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
- Complete the Pre-Activity Questions
- Read or Review the activity content.
- Complete the Post-Activity Test Questions and Evaluation.
- Learners who receive a grade of 60% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME, CNE, and/or CPE credit).
- CME and CNE credit will be issued appropriate certificate of completion.
- Others may request a “certificate of completion”.
- Learners should claim only the credit commensurate with the extent of their participation in the activity.
CE Inquiries/Special Needs
For all CE inquiries or special needs, please contact [email protected].
